On January 30, 2026, Ultragenyx Pharmaceutical Inc. announced it has resubmitted its Biologics License Application for UX111 gene therapy, with new long-term data supporting its case to the FDA for treating Sanfilippo syndrome type A. This submission aims for accelerated approval after addressing previous concerns and includes robust clinical data, anticipating a review period of up to six months.